Expanding Access and Optimizing the Use of CAR T-Cell Therapy in Multiple Myeloma
home / around-the-practice / expanding-access-and-optimizing-the-use-of-car-t-cell-therapy-in-multiple-myeloma
Panelists discuss how CAR T-cell therapy in relapsed/refractory multiple myeloma is supported by strong trial and real-world outcomes, and how optimizing patient selection and sequencing—while proactively addressing referral, logistical, toxicity, and insurance/financial barriers—can expand timely access and improve care delivery.
EP. 1: Evolving Evidence for CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
December 19th 2025Panelists discuss how pivotal trials and real-world evidence have reinforced CAR T-cell therapy’s high response rates, deep remissions, and durable outcomes in relapsed/refractory multiple myeloma.
